TEMPLATE PRESS RELEASE
VELCADE® (bortezomib) Approved For Previously Untreated Multiple Myeloma - VELCADE approved across all disease stages for broad spectrum of patients -
On June 2008, Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, announced the FDA approval of VELCADE for the treatment of previously untreated patients with multiple myeloma (MM), a fatal blood cancer who are not . . .
